Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Large Drop in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a large drop in short interest in July. As of July 31st, there was short interest totalling 1,890,000 shares, a drop of 6.4% from the July 15th total of 2,020,000 shares. Based on an average daily volume of 381,300 shares, the short-interest ratio is currently 5.0 days. Currently, 2.1% of the shares of the company are sold short.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, August 12th.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors have recently modified their holdings of the stock. Bleakley Financial Group LLC purchased a new stake in shares of Compass Therapeutics in the first quarter worth about $80,000. Simplicity Wealth LLC purchased a new stake in Compass Therapeutics in the 1st quarter worth approximately $80,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth approximately $41,000. SG Americas Securities LLC increased its holdings in shares of Compass Therapeutics by 22.7% during the 4th quarter. SG Americas Securities LLC now owns 47,624 shares of the company’s stock valued at $74,000 after purchasing an additional 8,817 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in shares of Compass Therapeutics in the 2nd quarter valued at $68,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Trading Down 1.7 %

Shares of NASDAQ:CMPX opened at $1.17 on Wednesday. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.57. The company has a market cap of $160.98 million, a PE ratio of -3.25 and a beta of 0.79. The company’s 50 day moving average is $1.04 and its 200 day moving average is $1.45.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). The business had revenue of $0.85 million during the quarter. Equities research analysts predict that Compass Therapeutics will post -0.39 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.